Infectious Disease

A recent study published this week, on April 1, 2025, found that pregnant women with SARS-CoV-2 infection may have a lower risk of developing long COVID compared to non-pregnant women. This finding, detailed in Nature Communications, shed light on pregnancy’s protective effects. The large-scale retrospective study, conducted under the guidance of researchers from Weill Cornell…

In 2024, the World Health Organization added 24 pathogens to its pandemic watchlist, including three that are zoonotic, meaning they spread from animals to humans. The newly added zoonotic diseases include avian influenza, mpox (previously known as monkeypox) and Sin Nombre virus, the latter of which jumps from mice to people and has a 30% fatality rate in…

Typical COVID-19 vaccines present fragments of the SARS-CoV-2 spike protein to the body, enabling the immune system to recognize and develop a defense against the virus. However, emerging variants are increasingly evading this immune response due to mutations in their receptor-binding domain (RBD), threatening the effectiveness of existing vaccines. This challenge has prompted research into…

OraSure Technologies is preparing for the upcoming World AIDS Day Virtual Summit and Celebration of Progress, scheduled for December 5, 2024, from 9:00 to 11:00 a.m. PST (12:00 – 2:00 p.m. EST). This digital event aligns with the 2024 World AIDS Day theme of “Collective Action: Sustain and Accelerate HIV Progress” and will bring together…

The FDA has approved Moderna’s and Pfizer’s updated COVID-19 vaccines targeting the KP.2 variant, an offshoot of the Omicron strain that was dominant in the U.S. in May 2024. More recently, KP.3 variants are gaining ground. As of August 20, 2024, CDC Nowcast projections estimate KP.3.1.1 accounts for approximately 37% of new COVID-19 cases in…

Moderna’s mRESVIA (mRNA-1345) has become the first mRNA-based vaccine for respiratory syncytial virus (RSV) to receive FDA approval. The vaccine is indicated for the prevention of lower respiratory tract disease caused by RSV infection in adults aged 60 years and older. This milestone marks Moderna’s second FDA-approved product after its COVID-19 vaccine. Earlier this year,…

[Updated May 21, 2024.] 2023 may not go down as the brightest year for the pharma sector, but the entry of Novo Nordisk’s Ozempic (semaglutide) into the ranks of top-selling drugs like Keytruda, Dupixent, and Eliquis signals a new era in the treatment of metabolic disease. Novo Nordisk’s sales jumped by more than one-third in…

Is aging a disease or a natural process? That question has emerged as a point of debate among researchers, medical professionals and philosophers. Some, like biogerontologist David Gems, argue that lines between aging and disease are frequently blurry, and that intervening in the aging process “protects against the totality of age-related diseases.” Other researchers such…

The recent emergence of H5N1 avian influenza in humans and many other animals has intensified global efforts to prepare for a potential pandemic. Public health agencies and international organizations are collaborating with pharmaceutical companies and academic institutions to develop vaccines, treatments, and strategies to mitigate the impact of an outbreak. The CDC, for instance, has…

Clostridioides difficile, commonly known as C. diff, is a significant health threat in the U.S. Recent estimates suggest that C. diff, a common bacteria, can cause infection in roughly 500,000 patients annually in the U.S., with around 30,000 of these cases resulting in death. “Actually, it’s more like 5 million when you think about it…

Abstract The vast majority of vaccines are prophylactic in nature. As a result, the demonstration of their efficacy paradoxically requires the infectious disease to occur among non-diseased study participants randomized between investigational vaccine and appropriate control groups. The statistics of vaccine efficacy (VE) calculation are nearly entirely and solely based on the number of observed…

Traditionally, the tech and biotech sectors in the U.S. have been concentrated in a handful of regions — most notably in areas such as Boston, Seattle, Silicon Valley and Southern California. But the Biden administration aims to distribute innovation more evenly through the U.S. To that end, the administration has designated 31 tech hubs across…

GSK (NYSE:GSK) is aiming to expand the label for its respiratory syncytial virus (RSV) vaccine Arexvy, which was the first to win FDA approval. The firm is now eyeing an extension of the label to include adults aged 50 to 59, bolstered by encouraging preliminary data from a phase 3 study. The recent data from…

Kathy Fernando, the senior vice president, head of Pfizer Ignite and Pfizer CentreOne, has had a professional trajectory marked by pivotal serendipities. One occurred when attending a seminar at the University of Pennsylvania, where she met Dr. Drew Weissman, a prominent immunologist and RNA vaccine researcher. Weissman, along with Katalin Karikó, recently received the Nobel…

 Data sourced from Our World in Data Cardiovascular disease and cancer remain the leading causes of death in the world, based on an analysis of data sources ranging from World Health Organization and Our World in Data. While respiratory illnesses were the third most common cause of death in 2019, deaths in this category…

As Pfizer and Moderna receive the FDA nod for COVID-19 boosters, their 2023 global sales projections appear to be just a fraction of the previous year’s. In 2022, Pfizer and its partner BioNTech jointly sold $56 billion worth of their Comirnaty COVID-19 vaccine, marking the best-selling drug of the year. Moderna’s Spikevax COVID-19 vaccine wasn’t…

When Keri Yale, the company’s head of patient affairs and engagement at Boehringer Ingelheim (BI), joined more than 25 years ago, she recognized a need to put patients at the center of the pharmaceutical industry. Since then, she has spearheaded a transformation towards greater patient centricity at the company that started with HIV/AIDS community engagement…

With updated COVID-19 boosters set to launch in the near future and COVID-related hospitalizations on the rise again, scrutiny is on the rise of emerging variants and the benefit-safety profile of COVID-19 vaccines. We performed a retrospective analysis of data from the Vaccine Adverse Event Reporting System (VAERS), focusing on the period covering the launch…

[Updated September 7. Article originally posted on July 21, 2023. Updates follow in bold:] The Vaccines and Related Biological Products Advisory Committee (VRBPAC) is backing a significant shift in the current COVID-19 vaccine strategy: a move from multivalent to monovalent vaccines focusing on the XBB lineage strains. More recently, the emergence of new variants such…

Against the backdrop of a nearly 16% spike in COVID-19 hospitalizations in late August, according to CDC data, federal authorities are gearing up to greenlight updated boosters. Moderna announced that its latest COVID vaccine is effective against this new strain. Meanwhile, Pfizer revealed positive preclinical data for its vaccine, developed in collaboration with BioNTech. In…

To date, there have been more than 770 million confirmed COVID-19 cases and nearly 7 million deaths from the virus, according to the World Health Organization (WHO). Vaccines remain one of the most potent tools in blunting the severity of SARS-CoV-2 infection, and vaccine developers have distributed more than 13.5 billion vaccine doses to date.…

Amid a backdrop of recent RSV vaccine approvals, GSK and Pfizer find themselves locked in a legal spat over alleged patent infringements. Both Big Pharma giants now possess the FDA’s blessing for their respective respiratory syncytial virus (RSV) vaccines. Pfizer’s recent win came with the second approval for its Abrysvo vaccine, which the company now…

COVID-19 vaccine giants Pfizer and Moderna are gearing up for a battle against the Eris SARS-CoV-2 subvariant, which has rapidly emerged as the dominant strain in the U.S. Eris now is responsible for more than one in five COVID infections, based on CDC estimates from August 6 to 19. Pfizer has noted that its most…

Moderna surged to prominence thanks to its rapid development of a competitive COVID-19 vaccine. Since the early days of the pandemic, however, the company has struggled to maintain its momentum. Year-to-date, its stock is down close to 40%, trading around $110 per share. Adapting to COVID-19 variants The company hopes that its development of vaccines…

From tackling the COVID-19 pandemic to paving the way for future global health challenges, RNA vaccines have rapidly gained attention in recent years. Researchers are already working to extend their capabilities for next-gen medicines. For example, scientists are working to create multivalent RNA formulations that can fight multiple virus variants. They are also exploring AI…